Together, We Can Make a Difference!

When we launched Movement Disorders Foundation (MDF) in 2018, we never imagined that it would become what it is today!

• Small in scope, large in impact, we still restrict 100% of the research funding we raise to research scientists, supporting innovative projects from conception and one-off testing to proof of concept.

• Since 2018, we've hosted in-person and virtual educational symposia featuring cutting-edge science and therapies presented by knowledgeable researchers. Our programs are uplifting experiences that reinforce the feeling of a strong, hopeful and united movement disorders community – all at absolutely no charge to participants.

• In 2023, Movement Disorders Foundation is preparing to release MDF Peer Connect, an online platform providing individuals with movement disorders the ability to connect with one another locally, nationally and the world over. Upon its launch, MDF will be the only organization in the cross-disease category to host such a network.

We write today to ask you to make a gift to Movement Disorders Foundation so that the next five years can be even more successful than the last. As we continue our journey, we want to thank each of you for embracing Movement Disorders Foundation and enabling us to grow and flourish.

Please make a gift today, and we can continue exploring, evolving, and growing together for years to come.

With gratitude,

Rajeev Kumar, MD; Betsy Mathies; Sara Minott; Betty Ross & Morris Susman, MD

Board of Directors, Movement Disorders Foundation

"Prevention is...like curing 10% of the population...."

Rajeev Kumar, MD, of the Rocky Mountain Movement Disorders Center and founding director of the Movement Disorders Foundation addresses the need for new ideas and research in the prevention and treatment of movement disorders.

"We'd love to have a therapy that prevented these diseases," says Dr. Kumar, "either for the general population or individuals at risk."

Non-genetic factors can play role in mortality risk

A greater number of CAG repeats within the HTT gene — the genetic cause of Huntington’s disease — is linked to earlier disease onset and death, but is not an independent predictor of mortality in people with the neurodegenerative disease, a study shows. Click here to learn more.

Gut microbiome at the center of PD pathogenesis

New research from the University of Alabama at Birmingham says the gut microbiome is involved in multiple pathways in the pathogenesis of Parkinson’s disease. The findings, published in Nature Communications, show a wide imbalance in microbiome composition in persons with Parkinson’s disease. Click here to learn more.

Drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns

Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline, according to new Phase 3 trial results. But the findings also raise some safety concerns because of the drug's association with certain serious adverse events. Click here to learn more.